Cryolipolysis With Colder Temp, Shorter Time Safe, Effective

This article originally appeared here.
Share this content:
Cryolipolysis With Colder Temp, Shorter Time Safe, Effective
Cryolipolysis With Colder Temp, Shorter Time Safe, Effective

THURSDAY, Sept. 21, 2017 (HealthDay News) -- Cryolipolysis with colder temperature and reduced treatment time is safe and effective for noninvasive reduction of submental fat, according to a study published online Sept. 12 in the Journal of Cosmetic Dermatology.

Hector Leal Silva, M.D., Ph.D., from UltraLaser in Monterrey, Mexico, and colleagues evaluated the safety and efficacy of cryolipolysis (CoolSculpting System; ZELTIQ Aesthetics, Pleasanton, Calif.) for noninvasive reduction of submental fat in 15 participants using lower temperatures and reduced treatment time (45 and 30 minutes at −12 and −15 degrees Celsius, respectively). Two treatments were performed 10 weeks apart.

The researchers found that the mean reduction measured by skin fold caliper was 33 percent (3.2 mm; P = 0.05), and by magnetic resonance imaging, the mean reduction was 1.78 mm. Before and after photographs were correctly identified 60 percent of the time by a blinded, independent panel. The majority of participants (80 percent) were satisfied or very satisfied with the treatment. Mild side effects resolved completely within 10 weeks, except for one case of hyperpigmentation, which resolved spontaneously within six months of the last treatment.

"Cryolipolysis with colder temperature and reduced treatment time continues to be effective and is safe for noninvasive reduction of the submental fat," the authors write.

ZELTIQ Aesthetics funded the study.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »